Molecular Express, Inc.

Molecular Express, Inc. is a biotechnology company that specializes in advanced formulation services to accelerate the development of vaccines, therapeutics, and small molecule drugs. The company utilizes its proprietary Molecular GPS™ and VesiVax® platforms for targeted drug delivery, nanoparticle design, and engineering. By leveraging these advanced delivery systems, the company provides essential support for protein processing, production, and rigorous analytical testing. Its expertise enables researchers to conjugate target molecules and stabilize compounds, ensuring they meet the required quality standards for preclinical and clinical development. Molecular Express, Inc. operates as a key research and development subsidiary of Molecular GPS Technologies™, collaborating with academic institutions and government agencies to bring innovative scientific research to market.

The company plays a vital role in life sciences by helping partners secure funding and grants to translate groundbreaking discoveries into viable clinical solutions. By providing efficient, scalable protein production and customized formulation services, it addresses significant bottlenecks in therapeutic development, such as supply constraints and manufacturing complexity. Through its work with the NIH and other organizations, Molecular Express contributes to public health by developing specialized treatments, including synthetic lung surfactants and immunomodulatory adjuvants. This collaborative, research-driven approach allows the company to support a wide range of projects, from oncology and infectious disease vaccines to novel medical imaging agents and addiction therapies, ultimately bridging the gap between bench-top research and real-world medical applications.